Description
Isocorydine is isolated from Dicranostigma leptopodum (Maxim.) Fedde (DLF). Isocorydine combines with Doxorubicin (DOX) has a promising potential to eradicate hepatocellular carcinoma (HCC).
Structural Formula
Isocorydine
Solubility
DMSO : 20 mg/mL(58.58 mM;Need ultrasonic)
Source
Plants >other families
Storage
4℃, protect from light
Shipping
Room temperature in continental US; may vary elsewhere.
SMILES
COC1=C2C3=C(C=C1OC)CCN(C)[C@@]3([H])CC4=CC=C(OC)C(O)=C24
In Vivo
Isocorydine (intraperitoneal injection; 0.4 mg/kg; every 2 days for 2 weeks) retards the tumor growth, but the combined treatment of Doxorubicin (DOX) or ICD significantly inhibits tumor growth.
In Vitro
Isocorydine (0-400 ug/ml; 48 hours) show a significant decrease in the IC50 for ICD and DOX, the CI values are 0.605, 0.644, 0.804, and 0.707 respectively for Huh-7, Hep-G2, SNU-449 and SNU-387. Isocorydine (0-400 ug/ml; 48 hours) abrogates DOX-induced upregulation of mesenchymal markers and the downregulation of epithelial markers in human HCC cell lines.
Datasheet 
